A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Trajan Group Acquires Axel Semrau GmbH

Global analytical science and device company Trajan Group Holdings Limited (ASX: TRJ) (Trajan or the Company) has completed the acquisition of Axel Semrau GmbH & Co. KG and Semrau Immobilien GmbH & Co. KG, the private business and properties of “Axel Semrau” based in Sprockhövel, Germany for €14.75 million and €2.25 million respectively. Adjustments, including accumulated undistributed profits total €2.85 million in favour of the sellers, to be paid by Trajan following Closing. Trajan is funding its current acquisition activities through a combination of cash and debt.

Axel Semrau employs just over 50 staff in Europe and develops and manufactures laboratory automation and chromatography software and detection systems. The company reported FY 21 (year ended Sept ’21) revenues of €14.9 million, and EBITDA of €1.46 million (normalized EBITDA of €1.67 million), unaudited.

Stephen Tomisich, Chief Executive Officer and Managing Director, Trajan stated, “We welcome the Axel Semrau team to the Trajan group. Trajan’s automation business and Axel Semrau have worked in close cooperation for several years and so we enter this new stage with a working relationship already well established. Axel Semrau owns and develops the CHRONOS intelligent sequencing software platform upon which Trajan’s automated workflows are built. We intend to further invest in CHRONOS in line with Trajan’s goal to simplify and automate complex analytical workflows.”

“Further, Axel Semrau’s automation business is highly synergistic with our own; both in terms of application areas and geographical coverage. Axel Semrau’s presence in chromatography and portable/on line gas detection also align with Trajan’s general direction.”

The two Managing Directors at Axel Semrau, Frank Sasse and Andreas Bruchmann and all other employees will continue in their current roles as part of the Trajan group. Dr Bruchmann commented “We welcome the opportunity to become part of the Trajan team. We have known Trajan for some time and find that our goals and values are aligned. We also see the intention of ongoing investment to drive growth in our business and capabilities.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

SABIC advises the project was initiated together with the dialysis department at Jessa Hospital, one of the largest non-university medical cluster in the Limburg region of Flanders, Belgium.
Dr. Sachita Shah, Sr. Director, Global Health, Butterfly Network, "Butterfly is proud to continue improving maternal health equity through Phase Two of the largest-scale handheld ultrasound distribution and training ever conducted in Sub-Saharan Africa. South Africa is an emerging market that continues to have disproportionately high rates of maternal mortality and stillbirth. Patients need easier access to antenatal imaging, and clinicians need better capabilities for screening high-risk conditions that lead to disproportionately worse pregnancy outcomes in rural areas in the public sector. Together with CHAI and GUSI, we can tackle this by making ultrasound much more accessible, so high-risk conditions can be identified earlier in care, which is known to improve outcomes.”
The clinical Study will enroll up to 97 patients at up to 12 European investigational sites. Completion of the study is expected this year, and results will support CE mark and pre-market approval submissions reports Vivasure Medical.
Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines

By using this website you agree to accept Medical Device News Magazine Privacy Policy